Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study.
OBJECTIVE
To evaluate the efficacy of otilonium bromide, a spasmolytic agent, in the treatment of irritable bowel syndrome using modern and validated diagnostic criteria.


METHODS
Three hundred and seventy-eight patients with irritable bowel syndrome were enrolled in the study. At entry, endoscopy/barium enema, clinical examination and laboratory tests were used to rule out organic diseases. After a 2-week placebo run-in, 325 patients were randomly assigned to receive either otilonium bromide 40 mg t.d.s. or placebo for 15 weeks. Abdominal pain, abdominal distension and disturbed defecation were scored at the beginning of the study and every 5 weeks. A global determination of well-being by visual analogue scale and the tenderness of the sigmoid colon were also scored.


RESULTS
The reduction in the number of abdominal pain episodes was significantly higher (P < 0.01) in otilonium bromide patients (55.3%) than in those taking placebo (39.9%) as was the severity of abdominal distension (42.0%, vs. 30.2%; P < 0.05). Bowel disturbance improved in both groups. but without any statistically significant difference. The visual analogue scale of well-being revealed a significant improvement (P < 0.05) in patients taking otilonium bromide. The investigators' global positive assessment was in favour of otilonium bromide (65.2%) compared with placebo (49.6%) (P < 0.01).


CONCLUSIONS
Otilonium bromide may represent an effective treatment for irritable bowel syndrome because it reduces its predominant symptom (abdominal pain/ discomfort) more than placebo does.
Battaglia
G
G
Unit of Gastroenterology, Hospital SS Giovanni e Paolo, Venice, Italy.
Morselli-Labate
A M
AM
Camarri
E
E
Francavilla
A
A
De Marco
F
F
Mastropaolo
G
G
Naccarato
R
R
D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006304:Health Status; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D010276:Parasympatholytics / Q000627:therapeutic use*; D010919:Placebos; D000644:Quaternary Ammonium Compounds / Q000009:adverse effects / Q000627:therapeutic use*
D010276:Parasympatholytics; D010919:Placebos; D000644:Quaternary Ammonium Compounds; C013934:octylonium